|Videos|July 7, 2021
The Potential Future Impact of CAR T Cell Therapy in Adult ALL
Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC
3
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
4
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
5